H.C. Wainwright initiated coverage of Perspective Therapeutics (CATX) with a Buy rating and $10 price target Perspective is a clinical-stage biotechnology company advancing targeted radiotherapy agents to address areas of serious unmet need within oncology, the analyst tells investors in a research note. The firm says PSV359 and VMT01/02 constitute upside potential for the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics initiated with a Buy at Brookline
- Tesla upgraded, Coinbase initiated: Wall Street’s top analyst calls
- Perspective Therapeutics initiated with an Outperform at Scotiabank
- Promising Outlook for Perspective Therapeutics: Buy Rating Backed by Positive Trial Data and Market Positioning
- Perspective continues to pursue dose escalation of 212PbVMT-alpha-NET
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue